



Attorney Docket No. 57559 (70207)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE FOR THE PATENT  
COOPERATION TREATY

APPLICANT(S) Gygi, et al.

EXAMINER: BULL, Christopher

U.S.S.N.: 10/781,047

GROUP: 1655


FILED (U.S.): February 17, 2004

CONFIRMATION 8390

FOR: ABSOLUTE QUANTIFICATION OF PROTEINS AND MODIFIED  
FORMS THEREOF BY MULTISTAGE MASS SPECTROMETRY

\*\*\*\*\*  
CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service, as Express Mail Label No. EV 755074015 US addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 30, 2006.

  
Helen Murray Tarbi

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO RESTRICTION REQUIREMENT**

In the Office Action dated May 5, 2006, restriction was required under 35 U.S.C. §121 to one of the following inventions:

- I. Claims 1-5 and 23-24, drawn to a method of making an isotopically labeled peptide internal standard;
- II. Claims 6-22 and 25, drawn to a method of determining the presence and/or quantity of a target polypeptide in a mixture;
- III. Claims 26-40, drawn to one or more isotopically labeled peptide internal standards; and

U.S.S.N. 10/781,047  
Inventors: Gygi et al.  
Attorney Docket No. 57559 (70207)  
Page 2 of 2

IV. Claims 41-46, drawn to kits comprising isotopically labeled peptide internal standards and software for accessing the information therein.

This application contains claims directed to the following patentably distinct species of the claimed invention:

Species I Mixtures of polypeptides as in claim 11;

Species II Amino acid residue modifications as in claim 27;


Species III Molecular pathways as in claim 31; and

Species IV Diseases as in claims 35-39.

Applicants hereby elect, with traverse, the inventions of Group II, claims 6-22 and 25, Species II for further examination in this application. Each of the claims are directed to a novel isotopically labeled peptide, its making or its use. Thus, there is a unifying inventive concept. Examination of all of the claims in this application is respectfully requested.

An early examination and notice of allowance are earnestly requested.

Respectfully submitted,

  
George W. Neuner  
(Reg. No. 26,964)

Date: June 30, 2006

EDWARDS ANGELL PALMER & DODGE LLP  
P.O. Box 55874  
Boston, MA 02205  
Telephone: 617-439-4444  
Customer No. 21874  
BOS2\_548096.1